Efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, by body region and PASI components in patients with moderate to severe plaque psoriasis (ESTEEM 1)

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2015
This article has no abstract
Epistemonikos ID: 07df1ee7f4a586b00eebe7800f41a0037f961818
First added on: Feb 07, 2025